ZOMETAŽ Official Site | Published Key Clinical Trials Of ZOMETAŽ (zoledronic acid)

View videos on bone
metastases and the ZOMETA
mechanism of action

Learn more about the ZOMETA(zoledronic acid) mechanism of action

For non-U.S. Healthcare Professionals: Get information about ZOMETA and its product characteristics

Learn more about ZOMETA product characteristics

Key Zometa (zoledronic acid) clinical trials

ZOMETA is the current standard of care for the prevention of skeletal-related events (SREs)

Published Clinical Trials

Kohno N.,
Zoledronic Acid Significantly Reduces Skeletal Complications Compared With Placebo in Japanese Women With Bone Metastases From Breast Cancer: A Randomized, Placebo-Controlled Trial
Journal of Clinical Oncology (2005)

Rosen L., et al.
Long-Term Efficacy and Safety of Zoledronic Acid in the Treatment of Skeletal Metastases in Patients with Nonsmall Cell Lung Carcinoma and Other Solid Tumors A Randomized, Phase III, Double-Blind, Placebo-Controlled Trial
Cancer (2004)

Saad F., et al.
Long-Term Efficacy of Zoledronic Acid for the Prevention of Skeletal Complications in Patients With Metastatic Hormone-Refractory Prostate Cancer
Journal of the National Cancer Institute (2004)

Lipton A., et al.
Zoledronic Acid Delays the Onset of Skeletal-Related Events and Progression of Skeletal Disease in Patients with Advanced Renal Cell Carcinoma
Cancer (2003)

Rosen L., et al.
Long-Term Efficacy and Safety of Zoledronic Acid Compared with Pamidronate Disodium in the Treatment of Skeletal Complications in Patients with Advanced Multiple Myeloma or Breast Carcinoma A Randomized, Double-Blind, Multicenter, Comparative Trial
Cancer (2003)

Rosen L., et al.
Zoledronic Acid Versus Placebo in the Treatment of Skeletal Metastases in Patients With Lung Cancer and Other Solid Tumors: A Phase III, Double-Blind, Randomized TrialThe Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group
Journal of Clinical Oncology (2003)

Saad F., et al.
A Randomized, Placebo-Controlled Trial of Zoledronic Acid in Patients With Hormone-Refractory Metastatic Prostate Carcinoma
Journal of the National Cancer Institute (2002)

Rosen L., et al.
Zoledronic Acid versus Pamidronate in the Treatment of Skeletal Metastases in Patients with Breast Cancer or Osteolytic Lesions of Multiple Myeloma: A Phase III Double-Blind, Comparative Trial
The Cancer Journal (2001)

Disclaimer: This is an international website for ZOMETA^® (zoledronic acid) and is intended for healthcare professionals outside the US. If you are a US resident, please click on the US flag at the top right corner of this page. The information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located.